SQNM, NVS And ALXN, 3 Health Care Stocks Pushing The Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 3 points (0.0%) at 15,545 as of Thursday, July 25, 2013, 12:49 PM ET. The NYSE advances/declines ratio sits at 1,346 issues advancing vs. 1,602 declining with 83 unchanged.

The Health Care sector currently sits up 0.5% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Humana ( HUM), down 2.3%, Intuitive Surgical ( ISRG), down 2.5%, WellPoint ( WLP), down 1.7%, Bristol-Myers Squibb Company ( BMY), down 1.1% and Baxter International ( BAX), down 1.1%. Top gainers within the sector include Boston Scientific ( BSX), up 11.6%, Vertex Pharmaceuticals ( VRTX), up 2.5%, Amgen ( AMGN), up 1.9%, Celgene Corporation ( CELG), up 1.7% and Biogen Idec ( BIIB), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Sequenom ( SQNM) is one of the companies pushing the Health Care sector lower today. As of noon trading, Sequenom is down $1.41 (-30.1%) to $3.28 on heavy volume. Thus far, 27.5 million shares of Sequenom exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $3.00-$3.42 after having opened the day at $3.07 as compared to the previous trading day's close of $4.69.

Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis. Sequenom has a market cap of $519.3 million and is part of the drugs industry. Shares are down 4.2% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Sequenom a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sequenom as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally high debt management risk and feeble growth in its earnings per share. Get the full Sequenom Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Novartis ( NVS) is down $0.60 (-0.8%) to $72.11 on heavy volume. Thus far, 1.4 million shares of Novartis exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $71.47-$72.11 after having opened the day at $71.92 as compared to the previous trading day's close of $72.71.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $177.9 billion and is part of the drugs industry. Shares are up 14.8% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $1.67 (-1.5%) to $108.09 on heavy volume. Thus far, 1.3 million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $107.70-$110.88 after having opened the day at $107.87 as compared to the previous trading day's close of $109.76.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $21.4 billion and is part of the drugs industry. Shares are up 16.7% year to date as of the close of trading on Wednesday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Insider Trading Alert - KSU, TLMR And SQNM Traded By Insiders

Insider Trading Alert - KSU, TLMR And SQNM Traded By Insiders

Sophiris Bio Tops Dollar-Stock Gainers on Trial Success of Cancer Treatment

Sophiris Bio Tops Dollar-Stock Gainers on Trial Success of Cancer Treatment

Insider Trading Alert - SQNM, OFIX And CIEN Traded By Insiders

Insider Trading Alert - SQNM, OFIX And CIEN Traded By Insiders

5 Stocks Insiders Love for 2016

5 Stocks Insiders Love for 2016